FDA Approves Pembrolizumab for High-Risk Early-Stage TNBC: 63% pCR in KEYNOTE-522

Executive Brief

News Report

The News: FDA approves pembrolizumab for high-risk early-stage TNBC.
Clinical Win: 63% pCR rate in KEYNOTE-522 trial supports its use.
Target Specialty: Oncology

Key Data at a Glance

Pathological Complete Response Rate: 63%
Event-Free Survival Event Rate: 16% (pembrolizumab) vs 24% (placebo)

On July 26, 2021, the FDA approved pembrolizumab (Keytruda) for high-risk early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, followed by adjuvant treatment after surgery. This approval is significant for healthcare professionals as it provides a new treatment option for patients with this aggressive cancer subtype, which is often challenging to manage.

Clinical Context

Triple-negative breast cancer (TNBC) is characterized by the absence of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 (HER2), making it particularly aggressive and difficult to treat. Patients with high-risk early-stage TNBC often face a higher likelihood of recurrence and poorer overall survival compared to other breast cancer subtypes. Current treatment typically involves chemotherapy, but the addition of immunotherapy has shown promise in improving outcomes. Pembrolizumab, a PD-1 inhibitor, has been evaluated in clinical trials for its effectiveness in combination with chemotherapy, leading to the recent FDA approval based on the results of the KEYNOTE-522 trial. This approval is expected to enhance treatment strategies for patients with high-risk early-stage TNBC, potentially leading to better pathological complete response (pCR) rates and improved long-term outcomes.

Key Findings

The trial enrolled 1,174 patients with newly diagnosed, previously untreated high-risk early-stage TNBC [1].

The primary endpoint was the rate of pathological complete response (pCR) [1].

Safety & Tolerability

The KEYNOTE-522 trial showed pembrolizumab reduced the pathological complete response (pCR) rate by 63% versus placebo (95% CI: 59.5, 66.4) [1].
Event rates: 16% of patients receiving pembrolizumab experienced an event-free survival (EFS) event compared to 24% in the placebo group (HR 0.63; 95% CI: 0.48, 0.82; p=0.00031) [1].

What This Means for Clinical Practice

Pembrolizumab is now indicated for use in patients with high-risk early-stage TNBC, providing an important addition to the treatment arsenal for this challenging cancer subtype. The 63% pCR rate observed in the KEYNOTE-522 trial supports its use in clinical practice, particularly for patients who may not respond adequately to chemotherapy alone. Clinicians should consider integrating pembrolizumab into treatment plans for eligible patients, as it may lead to improved outcomes and reduced recurrence rates. Ongoing monitoring and management of potential adverse effects will be essential to optimize patient care and ensure safety during treatment.

The approval of pembrolizumab also raises questions about how best to incorporate immunotherapy into existing treatment protocols for TNBC. As more data emerges from ongoing studies, clinicians will need to stay informed about evolving guidelines and recommendations to provide the best possible care for their patients.

Clinical Perspective

Workflow: Clinicians should integrate pembrolizumab into treatment plans for eligible TNBC patients.

Economics: The addition of pembrolizumab may improve long-term outcomes, potentially reducing healthcare costs associated with recurrence.

Patient Outcomes: Improved pCR rates with pembrolizumab could lead to better overall survival for patients with high-risk early-stage TNBC.

Dr. Rahul Verma, Oncology

FDA Approves Pembrolizumab for High-Risk Early-Stage TNBC: 63% pCR in KEYNOTE-522

Executive Brief

Key Data at a Glance

Clinical Context

Key Findings

Safety & Tolerability

What This Means for Clinical Practice

Clinical Perspective

References

Get weekly drug updates for Oncology in your inbox.

Related Drug Updates

WHO Updates Guidelines on BRCA Testing for Breast and Ovarian Cancer: Key Screening Recommendations

WHO Updates Guidelines on BRCA Testing for Breast and Ovarian Cancer Screening

USPSTF Updates BRCA Testing Guidelines: Who to Screen for Breast and Ovarian Cancer

Verified HCP Portal